Hielke Martijn de Vries
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hielke Martijn de Vries has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Oscar Roberto Brouwer
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital 1 Department of Urology Amsterdam, the Netherlands
10 shared publications - Maarten Albersen
Department of Urology, University Hospitals Leuven, Leuven, Belgium
4 shared publications Simon Horenblas
Department of Urology The Netherlands Cancer Institute‐Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands
4 shared publications- Manon T. A. Vreeburg
Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
3 shared publications - Michiel S. van der Heijden
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
3 shared publications - Paolo Dell’oGlio
Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications
Latest Publications
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- 23 June 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 675-681
Evaluating follow‐up in patients with lymph node‐negative penile cancer at a high‐volume centre
Objectives: To evaluate the current European Association of Urology/American Society of Clinical Oncology follow‐up (FU) schedule with routine use of ultrasonography (US) ± US‐guided fine‐needle aspiration cytology (FNAC) in patients with lymph node (LN)‐negative penile squamous cell carcinoma (PSCC). Patients and Methods: We evaluated FU outcomes for low‐risk clinically LN‐negative (cN0) and intermediate‐ to high‐risk sentinel node (SN) negative (pathological N‐stage [pN]0) patients with PSCC at a high‐volume centre. We analysed routine inguinal US ± FNAC (in case of a suspicious LN) during FU. A competing risk analysis was performed to calculate the cumulative risk of LN metastases in these groups, with local recurrence as competing risk. Results: A total of 201 patients with PSCC were analysed, with 2694 inguinal US investigations being evaluated. FNAC was performed during 270 US procedures (10.0%). A LN metastasis was found in four of 270 US + FNAC procedures (1.5%, 0.2% of all US). All tumours were intermediate‐ to high‐risk tumours. Three occurred within the first year after primary treatment, and one at 20 months. The cumulative risk of developing LN metastases in cN0 low‐risk tumours was 0% (no events occurred) and in SN‐negative intermediate‐ to high‐risk group 2.0%, both at 1 year of FU. Two (out of four) patients with LN recurrence died from disease. Conclusion: After adequate staging and treatment, patients with cN0/pN0 PSCC rarely develop LN metastasis during FU. As these metastases generally occur within 1 year after treatment, we recommend (3‐monthly) routine inguinal US only during the first year of FU. Thereafter, the frequency of FU visits and examinations can be reduced in patients capable of self‐examination of the penis, resulting in a substantial (up to a 50%) reduction of FU visits compared to current guideline recommendations.
- 23 June 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 675-681
Evaluating follow‐up in patients with lymph node‐negative penile cancer at a high‐volume centre
Objectives: To evaluate the current European Association of Urology/American Society of Clinical Oncology follow‐up (FU) schedule with routine use of ultrasonography (US) ± US‐guided fine‐needle aspiration cytology (FNAC) in patients with lymph node (LN)‐negative penile squamous cell carcinoma (PSCC). Patients and Methods: We evaluated FU outcomes for low‐risk clinically LN‐negative (cN0) and intermediate‐ to high‐risk sentinel node (SN) negative (pathological N‐stage [pN]0) patients with PSCC at a high‐volume centre. We analysed routine inguinal US ± FNAC (in case of a suspicious LN) during FU. A competing risk analysis was performed to calculate the cumulative risk of LN metastases in these groups, with local recurrence as competing risk. Results: A total of 201 patients with PSCC were analysed, with 2694 inguinal US investigations being evaluated. FNAC was performed during 270 US procedures (10.0%). A LN metastasis was found in four of 270 US + FNAC procedures (1.5%, 0.2% of all US). All tumours were intermediate‐ to high‐risk tumours. Three occurred within the first year after primary treatment, and one at 20 months. The cumulative risk of developing LN metastases in cN0 low‐risk tumours was 0% (no events occurred) and in SN‐negative intermediate‐ to high‐risk group 2.0%, both at 1 year of FU. Two (out of four) patients with LN recurrence died from disease. Conclusion: After adequate staging and treatment, patients with cN0/pN0 PSCC rarely develop LN metastasis during FU. As these metastases generally occur within 1 year after treatment, we recommend (3‐monthly) routine inguinal US only during the first year of FU. Thereafter, the frequency of FU visits and examinations can be reduced in patients capable of self‐examination of the penis, resulting in a substantial (up to a 50%) reduction of FU visits compared to current guideline recommendations.
- 25 April 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (9) , 728-735
Sexual functioning after penile cancer surgery: comparison between surgical approaches in a large patient cohort
Very few studies examine sexuality after penile cancer (PeCa) surgery and/or evaluate predictors of sexual satisfaction. Since 2016, primary PeCa patients at our institute routinely received the International Index of Erectile Function (IIEF-15) questionnaire: preoperatively (baseline) and 3-, 6-, 12- and 24-months postoperatively. We included patients who were surgically treated at our institute and completed the baseline and ≥1 follow-up questionnaire. Sexually active patients were divided into groups: wide local excision (WLE), glansectomy, partial penectomy and total penectomy with perineal urethrostomy. Linear mixed effects models were used for longitudinal analyses with repeated measures to examine predictors of overall sexual satisfaction. 647 patients with (suspected) PeCa were evaluated and received questionnaires. 543 (83.9%) returned the questionnaires. 242 were suitable for analysis. Preoperatively, only 55/242 (22.7%) were sexually active. Postoperatively, the number of sexually active patients increased for WLE (30.8% at baseline, 43.5% at two-year follow-up) and glansectomy (35.0% to 40.0%, both p < 0.001). Sexual satisfaction was below the level of healthy men in all patients, both pre- and postoperatively. Longer follow-up time, younger age, and penile-sparing surgeries were predictors for better sexual satisfaction. Our findings underscore the importance of considering penile-sparing surgical approaches in the treatment of PeCa when oncologically feasible. The significant improvements in sexual activity and sexual satisfaction following WLE and glansectomy support this approach. However, the overall sexual satisfaction after all PeCa surgery remains below the level of the healthy men, both pre- and post-operative, emphasizing the importance of guidance throughout the treatment trajectory.
- 25 April 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (9) , 728-735
Sexual functioning after penile cancer surgery: comparison between surgical approaches in a large patient cohort
Very few studies examine sexuality after penile cancer (PeCa) surgery and/or evaluate predictors of sexual satisfaction. Since 2016, primary PeCa patients at our institute routinely received the International Index of Erectile Function (IIEF-15) questionnaire: preoperatively (baseline) and 3-, 6-, 12- and 24-months postoperatively. We included patients who were surgically treated at our institute and completed the baseline and ≥1 follow-up questionnaire. Sexually active patients were divided into groups: wide local excision (WLE), glansectomy, partial penectomy and total penectomy with perineal urethrostomy. Linear mixed effects models were used for longitudinal analyses with repeated measures to examine predictors of overall sexual satisfaction. 647 patients with (suspected) PeCa were evaluated and received questionnaires. 543 (83.9%) returned the questionnaires. 242 were suitable for analysis. Preoperatively, only 55/242 (22.7%) were sexually active. Postoperatively, the number of sexually active patients increased for WLE (30.8% at baseline, 43.5% at two-year follow-up) and glansectomy (35.0% to 40.0%, both p < 0.001). Sexual satisfaction was below the level of healthy men in all patients, both pre- and postoperatively. Longer follow-up time, younger age, and penile-sparing surgeries were predictors for better sexual satisfaction. Our findings underscore the importance of considering penile-sparing surgical approaches in the treatment of PeCa when oncologically feasible. The significant improvements in sexual activity and sexual satisfaction following WLE and glansectomy support this approach. However, the overall sexual satisfaction after all PeCa surgery remains below the level of the healthy men, both pre- and post-operative, emphasizing the importance of guidance throughout the treatment trajectory.
- 25 February 2024
- Published by Wiley in BJU International
- Vol. 133 (5) , 596-603
Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival
Objective: To evaluate penile squamous cell carcinoma (PSCC) incidence and centralisation trends in the Netherlands over the past three decades, as well as the effect of centralisation of PSCC care on survival. Patients and methods: In the Netherlands PSCC care is largely centralised in one national centre of expertise (Netherlands Cancer Institute [NCI], Amsterdam). For this study, the Netherlands Cancer Registry, an independent nationwide cancer registry, provided per‐patient data on age, clinical and pathological tumour staging, follow‐up, and vital status. Patients with treatment at the NCI were identified and compared to patients who were treated at all other centres. The age‐standardised incidence rate was calculated with the European Standard Population. The probability of death due to PSCC was estimated using the relative survival. Multivariable Cox regression analysis was performed to evaluate predictors of survival. Results: A total of 3160 patients were diagnosed with PSCC between 1990 and 2020, showing a rising incidence ( P < 0.001). Annual caseload increased at the NCI (1% in 1990, 65% in 2020) and decreased at other (regional) centres (99% to 35%). Despite a relatively high percentage of patients with T2–4 (64%) and N+ (33%) at the NCI, the 5‐year relative survival was higher (86%, 95% confidence interval [CI] 82–91%) compared to regional centres (76%, 95% CI 73–80%, P < 0.001). Patients with a pathological T2 tumour were treated with glans‐sparing treatment more often at the reference centre than at the regional centres (16% vs 5.0%, P < 0.001). After adjusting for age, histological grading, T‐stage, presence of lymph node involvement and year of diagnosis, treatment at regional centres remained a predictor for worse survival (hazard ratio 1.22, 95% CI 1.05–1.39; P = 0.006). Conclusion: The incidence of PSCC in the Netherlands has been gradually increasing over the past three decades, with a noticeable trend towards centralisation of PSCC care and improved relative survival rate.
- 25 February 2024
- Published by Wiley in BJU International
- Vol. 133 (5) , 596-603
Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival
Objective: To evaluate penile squamous cell carcinoma (PSCC) incidence and centralisation trends in the Netherlands over the past three decades, as well as the effect of centralisation of PSCC care on survival. Patients and methods: In the Netherlands PSCC care is largely centralised in one national centre of expertise (Netherlands Cancer Institute [NCI], Amsterdam). For this study, the Netherlands Cancer Registry, an independent nationwide cancer registry, provided per‐patient data on age, clinical and pathological tumour staging, follow‐up, and vital status. Patients with treatment at the NCI were identified and compared to patients who were treated at all other centres. The age‐standardised incidence rate was calculated with the European Standard Population. The probability of death due to PSCC was estimated using the relative survival. Multivariable Cox regression analysis was performed to evaluate predictors of survival. Results: A total of 3160 patients were diagnosed with PSCC between 1990 and 2020, showing a rising incidence ( P < 0.001). Annual caseload increased at the NCI (1% in 1990, 65% in 2020) and decreased at other (regional) centres (99% to 35%). Despite a relatively high percentage of patients with T2–4 (64%) and N+ (33%) at the NCI, the 5‐year relative survival was higher (86%, 95% confidence interval [CI] 82–91%) compared to regional centres (76%, 95% CI 73–80%, P < 0.001). Patients with a pathological T2 tumour were treated with glans‐sparing treatment more often at the reference centre than at the regional centres (16% vs 5.0%, P < 0.001). After adjusting for age, histological grading, T‐stage, presence of lymph node involvement and year of diagnosis, treatment at regional centres remained a predictor for worse survival (hazard ratio 1.22, 95% CI 1.05–1.39; P = 0.006). Conclusion: The incidence of PSCC in the Netherlands has been gradually increasing over the past three decades, with a noticeable trend towards centralisation of PSCC care and improved relative survival rate.
- 10 January 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (2) , 243-244
Reply to Y.-N. Feng et al
- 10 January 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (2) , 243-244
Reply to Y.-N. Feng et al
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (31) , 4872-4880
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial
Durable antitumor activity to atezolizumab seen in a subset of patients with advanced penile cancer.
- 1 November 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (31) , 4872-4880
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial
Durable antitumor activity to atezolizumab seen in a subset of patients with advanced penile cancer.
- Open Access
- 30 August 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 166-169
International case series of metastasis to penis
Penile metastases are rare, with about 400 reported via case reports or small series. Under such circumstances coherent data about their behaviour may not be possible given vagaries of publication. For instance, one published meta‐analysis has proposed that malignant priapism contributes to worse survival, but this may be due to selection bias in published reports. We sought to evaluate clinical characteristics associated with survival in an international cohort of patients with metastases to the penis treated in major genitourinary cancer programmes.
- 30 August 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 166-169
Open AccessInternational case series of metastasis to penis
Penile metastases are rare, with about 400 reported via case reports or small series. Under such circumstances coherent data about their behaviour may not be possible given vagaries of publication. For instance, one published meta‐analysis has proposed that malignant priapism contributes to worse survival, but this may be due to selection bias in published reports. We sought to evaluate clinical characteristics associated with survival in an international cohort of patients with metastases to the penis treated in major genitourinary cancer programmes.
- 17 March 2022
- Published by Wiley in BJU International
- Vol. 130 (4) , 486-495
Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer
Objective: To determine the incidence and types of complications after dynamic sentinel node biopsy (DSNB) in patients with penile cancer (PeCa) and identify risk factors for the occurrence of postoperative complications. Patients and Methods: We evaluated 644 patients with PeCa (1284 DSNB procedures) with at least one clinically node negative (cN0) groin who underwent DSNB between 2011 and 2020 at a single high‐volume centre. The 30‐ and 30–90‐day postoperative complications were collected according to the modified Clavien–Dindo classification and the standardised methodology proposed by the European Association of Urology panel. Uni‐ and multivariable generalised linear mixed models were used to identify risk factors for the occurrence of complications per groin. Results: A 30‐day postoperative complication occurred in 14% of groins ( n = 186), of which 94% were mild to moderate. Wound infection and lymphocele formation were most common. A 30–90‐day postoperative complication occurred in 3.4% of the groins, all of which were mild or moderate (Grade I–II). The number of removed lymph nodes (LNs) per groin was the main independent predictor for any 30‐day complications and Grade ≥II complications (odds ratio 1.40; P < 0.001). There was an increase in the probability of postoperative complications with the number of LNs removed after accounting for all confounders. Conclusions: Despite being less morbid than (modified) inguinal LN dissection, DSNB is still associated with a considerable risk of postoperative mild‐to‐moderate complications. This risk increases with increasing number of LNs removed. Further procedural refinement aimed at removing the true sentinel node(s) only, may help further reduce the morbidity of surgical staging in PeCa.
- 17 March 2022
- Published by Wiley in BJU International
- Vol. 130 (4) , 486-495
Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer
Objective: To determine the incidence and types of complications after dynamic sentinel node biopsy (DSNB) in patients with penile cancer (PeCa) and identify risk factors for the occurrence of postoperative complications. Patients and Methods: We evaluated 644 patients with PeCa (1284 DSNB procedures) with at least one clinically node negative (cN0) groin who underwent DSNB between 2011 and 2020 at a single high‐volume centre. The 30‐ and 30–90‐day postoperative complications were collected according to the modified Clavien–Dindo classification and the standardised methodology proposed by the European Association of Urology panel. Uni‐ and multivariable generalised linear mixed models were used to identify risk factors for the occurrence of complications per groin. Results: A 30‐day postoperative complication occurred in 14% of groins ( n = 186), of which 94% were mild to moderate. Wound infection and lymphocele formation were most common. A 30–90‐day postoperative complication occurred in 3.4% of the groins, all of which were mild or moderate (Grade I–II). The number of removed lymph nodes (LNs) per groin was the main independent predictor for any 30‐day complications and Grade ≥II complications (odds ratio 1.40; P < 0.001). There was an increase in the probability of postoperative complications with the number of LNs removed after accounting for all confounders. Conclusions: Despite being less morbid than (modified) inguinal LN dissection, DSNB is still associated with a considerable risk of postoperative mild‐to‐moderate complications. This risk increases with increasing number of LNs removed. Further procedural refinement aimed at removing the true sentinel node(s) only, may help further reduce the morbidity of surgical staging in PeCa.
- 20 December 2021
- Published by Wiley in BJU International
- Vol. 130 (1) , 126-132
Clinicopathological predictors of finding additional inguinal lymph node metastases in penile cancer patients after positive dynamic sentinel node biopsy: a European multicentre evaluation
Objective: To develop a predictive model for additional inguinal lymph node metastases (LNM) at inguinal lymph node dissection (ILND) after positive dynamic sentinel node biopsy (DSNB) using DSNB characteristics to identify a patient group in which ILND might be omitted. Patients and Methods: We conducted a retrospective study of 407 inguinal basins with a positive DSNB in penile cancer patients who underwent subsequent ILND from seven European centres. From the histopathology reports, the number of positive and negative lymph nodes, presence of extranodal extension and size of the metastasis were recorded. Using bootstrapped logistic regression, variables were selected for the clinical prediction model based on the optimization of Akaike's information criterion. The area under the curve (AUC) of the receiver‐operating characteristic curve was calculated for the resulting model. Decision curve analysis (DCA) was used to evaluate the clinical utility of the model. Results: Of the positive DSNBs, 64 (16%) harboured additional LNM at ILND. Number of positive nodes at positive DSNB (odds ratio [OR] 2.19, 95% confidence interval (CI) 1.17–4.00; P = 0.01) and largest metastasis size in mm (OR 1.06, 95% CI 1.03–1.10; P = 0.001) were selected for the clinical prediction model. The AUC was 0.67 (95% CI 0.60–0.74). The DCA showed no clinical benefit of using the clinical prediction model. Conclusion: A small but clinically important group of basins harbour additional LNM at completion ILND after positive DSNB. While DSNB characteristics were associated with additional LNM, they did not improve the selection of basins in which ILND could be omitted. Thus, completion ILND remains necessary in all basins with a positive DSNB.
- 20 December 2021
- Published by Wiley in BJU International
- Vol. 130 (1) , 126-132
Clinicopathological predictors of finding additional inguinal lymph node metastases in penile cancer patients after positive dynamic sentinel node biopsy: a European multicentre evaluation
Objective: To develop a predictive model for additional inguinal lymph node metastases (LNM) at inguinal lymph node dissection (ILND) after positive dynamic sentinel node biopsy (DSNB) using DSNB characteristics to identify a patient group in which ILND might be omitted. Patients and Methods: We conducted a retrospective study of 407 inguinal basins with a positive DSNB in penile cancer patients who underwent subsequent ILND from seven European centres. From the histopathology reports, the number of positive and negative lymph nodes, presence of extranodal extension and size of the metastasis were recorded. Using bootstrapped logistic regression, variables were selected for the clinical prediction model based on the optimization of Akaike's information criterion. The area under the curve (AUC) of the receiver‐operating characteristic curve was calculated for the resulting model. Decision curve analysis (DCA) was used to evaluate the clinical utility of the model. Results: Of the positive DSNBs, 64 (16%) harboured additional LNM at ILND. Number of positive nodes at positive DSNB (odds ratio [OR] 2.19, 95% confidence interval (CI) 1.17–4.00; P = 0.01) and largest metastasis size in mm (OR 1.06, 95% CI 1.03–1.10; P = 0.001) were selected for the clinical prediction model. The AUC was 0.67 (95% CI 0.60–0.74). The DCA showed no clinical benefit of using the clinical prediction model. Conclusion: A small but clinically important group of basins harbour additional LNM at completion ILND after positive DSNB. While DSNB characteristics were associated with additional LNM, they did not improve the selection of basins in which ILND could be omitted. Thus, completion ILND remains necessary in all basins with a positive DSNB.